Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials
| Autor: | Göran Gustafsson, Niels Clausen, S. O. Lie, Lotta Mellander, Henrik Hasle, Erik Forestier, Liisa Hovi, Jonas Abrahamsson, Gudmundur Jonmundsson |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
Chemotherapy business.industry medicine.medical_treatment Cytogenetics Hematology Aplasia medicine.disease 3. Good health Surgery Transplantation 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure El Niño In vivo 030220 oncology & carcinogenesis Internal medicine Medicine Bone marrow Myeloid leukaemia business 030215 immunology |
| Zdroj: | British Journal of Haematology. 122:217-225 |
| ISSN: | 0007-1048 |
| Popis: | Summary. Three consecutive protocols for childhood acute myeloid leukaemia (AML) have been used in the Nordic countries since 1984: the Nordic Society for Paediatric Haematology and Oncology (NOPHO)-AML84 was of moderate intensity, NOPHO-AML88 of high intensity with upfront loading and aggressive consolidation. NOPHO-AML93 utilized the same treatment blocks as NOPHO-AML88, but after the first block those children with a hypoplastic non-leukaemic bone marrow were allowed to recover from aplasia. Poor responders received intensified induction therapy. Between January 1993 and December 2000, 219 children without Down's syndrome were entered on NOPHO-AML93. Compared with NOPHO-AML88, the event-free survival (EFS) at 7 years increased from 41% to 49% (P = 0·06) and 7-year overall survival increased from 47% to 64% (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text